Multimodal first-in-class cancer therapeutics against intractable targets.
Therapeutic Window for Cancer Immunotherapy
GO Therapeutics is developing a range of cancer drug candidates that are exquisitely tumor specific.
We are developing antibodies against a novel class of tumor-specific glycoprotein antigens. These antigens are not found on healthy cells, making them ideal targets for bi-specific antibody T-cell engagement, CAR-T and ADC therapies. GO’s lead antibody development program is based on a bispecific antibody for T cell-redirection therapy.
Addressing novel targets
with different biology.
ADVANCED TOOLS AND
Unlocking the potential of ADCs, T-cell
bi-specifics, and immune-based cell therapies.
WHAT'S IN THE PIPELINE